Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer.
Hart SN, Ellingson MS, Schahl K, Vedell PT, Carlson RE, Sinnwell JP, Barman P, Sicotte H, Eckel-Passow JE, Wang L, Kalari KR, Qin R, Kruisselbrink TM, Jimenez RE, Bryce AH, Tan W, Weinshilboum R, Wang L, Kohli M. Hart SN, et al. Among authors: bryce ah. BMJ Open. 2016 Apr 15;6(4):e010332. doi: 10.1136/bmjopen-2015-010332. BMJ Open. 2016. PMID: 27084275 Free PMC article.
A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study.
Aggarwal R, Bryce A, Ryan CJ, Harzstark A, Derleth C, Kim W, Friedlander T, Lin AM, Rodvelt-Bagchi T, Dhawan M, Zhang L, Lee M, Siebeneck E, Hough J, Small EJ. Aggarwal R, et al. Urol Oncol. 2017 Apr;35(4):149.e7-149.e13. doi: 10.1016/j.urolonc.2016.11.005. Epub 2017 Feb 1. Urol Oncol. 2017. PMID: 28161323 Clinical Trial.
Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery.
Bryce AH, Egan JB, Borad MJ, Stewart AK, Nowakowski GS, Chanan-Khan A, Patnaik MM, Ansell SM, Banck MS, Robinson SI, Mansfield AS, Klee EW, Oliver GR, McCormick JB, Huneke NE, Tagtow CM, Jenkins RB, Rumilla KM, Kerr SE, Kocher JA, Beck SA, Fernandez-Zapico ME, Farrugia G, Lazaridis KN, McWilliams RR. Bryce AH, et al. Oncotarget. 2017 Apr 18;8(16):27145-27154. doi: 10.18632/oncotarget.16057. Oncotarget. 2017. PMID: 28423702 Free PMC article.
A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone.
Wang L, Dehm SM, Hillman DW, Sicotte H, Tan W, Gormley M, Bhargava V, Jimenez R, Xie F, Yin P, Qin S, Quevedo F, Costello BA, Pitot HC, Ho T, Bryce AH, Ye Z, Li Y, Eiken P, Vedell PT, Barman P, McMenomy BP, Atwell TD, Carlson RE, Ellingson M, Eckloff BW, Qin R, Ou F, Hart SN, Huang H, Jen J, Wieben ED, Kalari KR, Weinshilboum RM, Wang L, Kohli M. Wang L, et al. Among authors: bryce ah. Ann Oncol. 2018 Feb 1;29(2):352-360. doi: 10.1093/annonc/mdx689. Ann Oncol. 2018. PMID: 29069303 Free PMC article. Clinical Trial.
Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer.
McCleary-Wheeler AL, Carr RM, Palmer SR, Smyrk TC, Allred JB, Almada LL, Tolosa EJ, Lamberti MJ, Marks DL, Borad MJ, Molina JR, Qi Y, Lingle WL, Grothey A, Pitot HC, Jatoi A, Northfelt DW, Bryce AH, McWilliams RR, Okuno SH, Haluska P, Kim GP, Colon-Otero G, Lowe VJ, Callstrom MR, Ma WW, Bekaii-Saab T, Hung MC, Erlichman C, Fernandez-Zapico ME. McCleary-Wheeler AL, et al. Among authors: bryce ah. Pancreatology. 2020 Jan;20(1):101-109. doi: 10.1016/j.pan.2019.11.011. Epub 2019 Nov 21. Pancreatology. 2020. PMID: 31787526 Free PMC article. Clinical Trial.
Assessment of isochromosome 12p and 12p abnormalities in germ cell tumors using fluorescence in situ hybridization, single-nucleotide polymorphism arrays, and next-generation sequencing/mate-pair sequencing.
Freitag CE, Sukov WR, Bryce AH, Berg JV, Vanderbilt CM, Shen W, Smadbeck JB, Greipp PT, Ketterling RP, Jenkins RB, Herrera-Hernandez L, Costello BA, Thompson RH, Boorjian SA, Leibovich BC, Jimenez RE, Murphy SJ, Vasmatzis G, Cheville JC, Gupta S. Freitag CE, et al. Among authors: bryce ah. Hum Pathol. 2021 Jun;112:20-34. doi: 10.1016/j.humpath.2021.03.008. Epub 2021 Mar 31. Hum Pathol. 2021. PMID: 33798590
Phase II trial of oral topotecan and intravenous carboplatin with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: A North Central Cancer Treatment Group Study.
Bryce AH, Mattar B, Hillman SL, Adjei AA, Kugler JW, Rowland K Jr, Wender DB, Soori G, Perez EA, Jett JR. Bryce AH, et al. Am J Clin Oncol. 2010 Aug;33(4):353-7. doi: 10.1097/COC.0b013e3181b0c27f. Am J Clin Oncol. 2010. PMID: 19935387 Free PMC article. Clinical Trial.
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J. Weber JS, et al. Lancet Oncol. 2015 Apr;16(4):375-84. doi: 10.1016/S1470-2045(15)70076-8. Epub 2015 Mar 18. Lancet Oncol. 2015. PMID: 25795410 Clinical Trial.
153 results